ArticleCureus2023
Bevacizumab-Induced Nephropathy Presenting as Crescentic Glomerulopathy.
Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Glomerular disease associated with cancer: a case series of paraneoplastic nephrotic syndrome.Frontiers in medicine · 2025Article
- Drug-Related Glomerular Phenotypes: A Global Pharmacovigilance Perspective.Journal of clinical medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bevacizumab-induced nephropathy is a common adverse event observed in patients who receive chemotherapy. These patients usually present with hypertension and nephrotic range proteinuria. Thrombotic microangiopathy is the characteristic histologic pattern of bevacizumab-induced nephropathy. However, a few cases reported IgA vasculitis with nephritis as an unusual pattern. In this case report, we describe a patient diagnosed with bevacizumab-induced nephropathy with a distinctive histologic pattern demonstrating focal proliferative crescentic glomerulonephritis with polyclonal immune complex deposition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.